Why should your R&D and IP departments collaborate?
A solid patent strategy is just as important as a well-planned business strategy for a corporation. With thousands of patents being filed every year by technology giants, developing a patent strategy is more challenging than ever. Business strategy is always market-driven, and so should be a patent strategy. It is important to understand the current […]
The most underrated feature of GreyB’s IDS Manager
When I joined GreyB last year as part of the marketing team, my first week was dedicated to learning about the in-house tools and understanding what sets our tools apart. One tool which caught my attention, given the queries we received on it, was the IDS Manager. Further, the keyword that separated GreyB’s tool from the […]
How to use patent analytics in your open innovation process?
To leverage external smarts, P&G launched its Connect and Develop (C+D) program in 2002. The C+D website later (www.pgconnectdevelop.com) became the binder for innovators, scientists, engineers, university researchers, and entrepreneurs with P&G. By 2014, more than 35% of new product launches were due to leveraging external smarts – the percentage was 15 in 2000. The […]
Case Study: How patent analytics enhanced the competitive analysis?
Intelligence today is about using the collective knowledge of the organisation to reach an advantageous position in industry” ~~ Stevan Dedijer, the Father of Business Intelligence Walmart launched its intelligent food system for produce in March 2018, and it must not have come as a surprise to other players if they had been tracking Walmart’s […]
The Stelara Patent Thicket: Patents Expiring in 2023
If Drug research and development is your bread and butter, you must be familiar with the wonders of Stelara. For the uninitiated, Stelara is the brand name of the drug Ustekinumab, which is developed by Janssen Pharmaceuticals, a subsidiary of J&J. It is used for the treatment of Crohn’s disease, ulcerative colitis, plaque psoriasis, and […]
Life of a Paralegal before and after the IDS Manager
“You don’t know the value of the best until you’ve experienced the worst,” I blurted out loud as I went through the journal of a paralegal, amazed at how his life took a turn for the best. While scrolling through my daily emails, I stumbled across an email shared by one of our IDS Manager […]
List – 29 Drug Patents that are Expiring in 2030
The list includes not just the drug names but also other information like treatment, ingredients, and the disease they cure, which could help them (you) easily choose the drug most profitable to develop a generic version. Without any delay, here is the list of drugs. The article has a list of drug patents in 2030. […]
List – 44 Drug Patents that are Expiring in 2029
The list includes not just the drug names but also other information like yearly sales, treatment, ingredients, and the disease they cure which could help them (you) easily choose the drug most profitable to develop a generic version. Without any delay, here is the list of drugs. Thank us later! The article has a list […]
5 Best practices to follow while filing Information Disclosure Form (IDS)
Our operational costs have been reduced by 50% and prosecution time is 30% faster, which has led to a 25% increase in profit. – Mike, one of our clients, filed over 20,000 (Information Disclosure Form) IDS last year. Did you know that it isn’t just Mike? A number of our clients were concentrating the majority […]
Case Study: How Patents Unmasked Alibaba’s Secret Partner?
How would you know about a startup or a new player about which there is too little or nothing written on the internet? It won’t appear on Bloomberg or Crunchbase. And, you cannot miss it being in your market research report just because they haven’t made it to the news yet. What if such a […]
List – 30 Drug Patents that are Expiring in 2028
With the huge growth in the generic drug market, there is no doubt that generic companies (you too?) are searching for drugs with a soon-to-be-expired label. So we decided to further up our game and extract all the drug patents expiring this decade. So far we have published the drug patents expiring in 2026 and […]
Patent Landscape Study: Strategy against Tech Companies’ Invasion
About ten years ago, traditional watchmakers—companies like Tag Heuer, Swatch, and Timex—entered dangerous waters. Tech companies were preparing to introduce the modern smartwatch—a grave threat to the watchmakers’ bottom line. Of course, most companies are vulnerable to tech disruption. But the watchmakers’ position was especially precarious for another reason: They didn’t seem to have any […]
Patent Landscape: A New Approach to find Relevant Insights
Patent landscapes have been in the IP industry for a very long time and have been majorly used to track the number of patent filings, the number of competitors, the number of collaborations, and so on. But, there is much more to these landscapes than counting numbers. These days, executives are least worried about how […]
List – 59 Drug Patents that are Expiring in 2027
A drug used for the treatment of prostate cancer is going off-patent in 2027. Another one, which ministers to Type 2 Diabetes is going off-patent in the same year too. And there are so many more of them, all going off-patent in 2027! To make your work easy, we collected not just the names of […]
List – 55 Drug Patents that are Expiring in 2026
With the huge growth in the generic drug market, there is no doubt that generic companies (hey there!) are searching for drugs with a soon-to-be-expired label. To make their (your) work easy, we collected not just the drug names, but also included other information like yearly sales, treatment, ingredients, and the disease they cure which […]
We found this GEM patent for our client
Not all that shines is gold and not every patent in your portfolio is a gem patent. Every inventor has a plan to eventually monetize their patent. But almost 80% of patents never see the light of any licensing, litigation, or overlap. And it is those 20% patents that seek revenue for their owners – […]
